The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia

Leukemia

Volumn 23, Issue 1, 2009, Pages 95-103

  Toki, T ^a   Kanezaki, R ^a   Adachi, S ^b   Fujino, H ^b   Xu, G ^a   Sato, T ^a   Suzuki, K ^a   Tauchi, H ^c   Endo, M ^d   Ito, E ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MCL 1; RAS PROTEIN; STEM CELL FACTOR;

ACUTE MEGAKARYOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSIENT LEUKEMIA;

EID: 58249108548     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.267     Document Type: Article

References (27)

1. Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/ or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997; 21: 97-101.
2. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210-2214.
3. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25: 5442-5447.
4. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107: 4606-4613.
5. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C et al. Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood 2008; 111: 2991-2998.
6. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 2005; 16: 137-147.
7. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006; 103: 3339-3344.
8. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F et al The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
9. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005; 217: 126-134.
10. Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Br J Haematol 2008; 141: 681-688.
11. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65-75.
12. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484-2490.
13. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-1326.
14. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/ 2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278 18811-18816.
15. Hirose Y, Kudo K, Kiyoi H, Hayashi Y, Naoe T, Kojima S. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome. Leukemia 2003; 17: 2250-2252.
16. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2007; 13: 5398-5405.
17. Miyauchi J, Ito Y, Kawano T, Tsunematsu Y, Shimizu K. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: A report of four autopsy cases and proposal of a hypothesis. Blood 1992; 8: 1521-1527.
18. Teyssier-Le Discorde M, Prost S, Nandrot E, Kirszenbaum M. Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression during human embryonic haemopoiesis. Br J Haematol 1999; 107 247-253.
19. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613-619.
20. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B et al Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644-3654.
21. Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwig WD et al Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992; 80: 1199-1206.
22. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41: 1046-1055.
23. Hattori H, Matsuzaki A, Suminoe A, Ihara K, Nakayama H, Hara T. High expression of platelet-derived growth factor and transforming growth factor-β1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br J Haematol 2001; 115: 472-475.
24. Ogawa J, Kanegane H, Tsuneyama K, Kanezaki R, Futatani T, Nomura K et al. Platelet-derived growth factor may be associated with fibrosis in a Down syndrome patient with transient myeloproliferative disorder. Eur J Hematol 2008; 81: 58-64.
25. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J 2005; 19: 1-11.
26. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-777.
27. Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Yoshii J, Yanase K et al Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17: 899-904.